2025 Biosimilars Pharmaceutical Companies 
Express Pharma
MARCH 2, 2025
Continued strategic focus on North America: US market accounts for anywhere between 30 per cent to 60 per cent of annual revenues for Leading Pharmaceutical companies in India. Companies will continue to acquire leadership capabilities with focus on these markets.
Pharma Marketing Network
MARCH 20, 2025
With the rapid expansion of digital platforms, evolving patient expectations, and the increasing role of AI-driven marketing, pharmaceutical companies and healthcare brands are allocating more resources to advertising in 2025. Second, competition among pharmaceutical brands is growing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
MARCH 16, 2025
In India, pharmaceutical companies responded to global environmental concerns and government mandates by adopting greener manufacturing techniques. To move from generics to novel drug development, Indian companies must invest heavily in R&D for innovative therapies like biosimilars, cell and gene therapies, and specialty drugs.
European Pharmaceutical Review
FEBRUARY 27, 2024
Novel biosimilar approval In the same month, the US Food and Drug Administration (FDA) approved Amgen’s Wezlana (ustekinumab-auub) as the first biosimilar to reference blockbuster drug Stelara (ustekinumab). The post Amgen opens its most advanced manufacturing facility to date appeared first on European Pharmaceutical Review.
pharmaphorum
OCTOBER 13, 2022
ResearchandMarkets also recently published a report , which highlighted only biosimilars as the emerging treatments for osteoporosis. Emerging research and biosimilars. Sandoz recently announced positive clinical trial results from a phase 1/3 into its biosimilar to denosumab.
FDA Law Blog: Biosimilars
MARCH 18, 2025
On March 13, 2025, the Federal Circuit ventured into the world of reissued patents and PTE. ( Specifically, the Court focused on the purpose: to compensate pharmaceutical companies for the effective truncation of their patent terms while waiting for regulatory approval of new drug applications. In Merck Sharp & Dohme Corp.
PharmaShots
JUNE 7, 2023
Our team at PharmaShots has summarized 16 key events of the biosimilar space of May 2023 1. based on change from baseline on a standardized DAS28-CRP which evaluates the severity of RA using clinical and laboratory data Additionally, the company initiates PK study for AVT05 in Jan 2023. 84% vs 64%) & 2yr. (60%
Expert insights. Personalized for you.
99 
Let's personalize your content